BDSX News and Press, Biodesix Inc. From 06/01/22

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the 42nd Annual William Blair Growth Stock Conference being held June 6-9, 2022 at the L...

Biodesix has been a terrible business and stock since its offering. Even a short-lived pandemic-related momentum run could not inspire confidence or profits. Right now, the situation is extremely speculative, with no green shoots available here. For further details see: ...

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present virtually at the H.C. Wainwright Global Investment Conference being held May 23-25, 2022. ...

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announces new clinical utility data highlighting the impact of the Nodify XL2 Risk Assessment Test on clinical management decisions in patients with lung nodules will be prese...

Image source: The Motley Fool. Biodesix, Inc. (NASDAQ: BDSX) Q1 2022 Earnings Call May 11, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Biodesix, Inc. (BDSX) Q1 2022 Earnings Call Transcript

Biodesix, Inc. (BDSX) Q1 2022 Earnings Conference Call May 11, 2022, 08:00 ET Company Participants Chris Brinzey - IR Scott Hutton - President, CEO & Director Robin Cowie - CFO, Secretary & Treasurer Conference Call Participants Brian Weinstein - William Blair & Company Kyle Mikso...

Gainers: Blue Water Vaccines (BWV) +18%. Oscar Health (OSCR) +13%. Veru (VERU) +10%. Zai Lab (ZLAB) +8%. Better Therapeutics (BTTX) +6%. Losers: Inovio Pharmaceuticals (INO) -32%. iTeos Therapeutics (ITOS) -32%. Arcus Biosciences (RCUS) -28%. Akand...

Biodesix press release (NASDAQ:BDSX): Q1 GAAP EPS of -$0.50 misses by $0.08. Revenue of $6.55M (-77.3% Y/Y) beats by $0.08M. Shares up 12% PM. The company reaffirms FY2022 financial outlook and expects to generate between $37.5M and $39.5M in total revenue vs. consensus of $38.41M. ...

First quarter 2022 core Lung Diagnostic revenue of $4.6 million increased 17% over the comparable period in 2021; Continued to strengthen financial position through an additional $27.4 million in debt and equity funding during second quarter 2022; Conference Call and W...

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the first quarter ended March 31, 2022 before the open of trading on Wednesday, May 11. Biodesix’s manage...